Sam Brusco, Associate Editor02.24.22
Artificial intelligence (AI) powered care coordination firm Viz.ai has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Viz ANEURYSM AI algorithm to spot suspected cerebral aneurysms. The population health tool aims to help standardize aneurysm workflows so patients receive appropriate follow-up care, and offer hospitals and payers financial benefits.
Viz ANEURYSM demonstrated 94 percent accuracy using 528 CTAs with 674 aneurysms distributed across anterior and posterior cerebral vascular territories in a University of Toronto study.
“[Aneurysms] can be often missed because they require a very methodical diagnostic approach,” Dr. Vitor Mendes Pereira, director of Endovascular Research and Innovation, University of Toronto told the press. “The Viz.ai aneurysm algorithm was able to detect cerebral aneurysms in consecutive CTAs. The model has demonstrated that a deep learning AI algorithm can achieve clinically useful levels of accuracy for clinical decision support and will help us to improve how we help aneurysm patients.”
“Viz ANEURYSM has the potential to significantly increase the number of aneurysms detected and clinically followed,” said Jayme Strauss, chief clinical officer of Viz.ai. “The combination of detection with an ability to schedule patients for neurovascular specialist follow-up is an important advancement for aneurysm patients, helping patients obtain the necessary follow-up from this potentially deadly disease and driving improved outcomes on the population health level.”
The Viz ANEURYSM module is the latest addition to the company’s Viz Intelligent Care Coordination Platform, which is clinically validated and reimbursed by Medicare. Its clinical utility spans ischemic and hemorrhagic stroke, pulmonary embolism and aortic disease and is used in over 1,000 hospitals.
Viz ANEURYSM demonstrated 94 percent accuracy using 528 CTAs with 674 aneurysms distributed across anterior and posterior cerebral vascular territories in a University of Toronto study.
“[Aneurysms] can be often missed because they require a very methodical diagnostic approach,” Dr. Vitor Mendes Pereira, director of Endovascular Research and Innovation, University of Toronto told the press. “The Viz.ai aneurysm algorithm was able to detect cerebral aneurysms in consecutive CTAs. The model has demonstrated that a deep learning AI algorithm can achieve clinically useful levels of accuracy for clinical decision support and will help us to improve how we help aneurysm patients.”
“Viz ANEURYSM has the potential to significantly increase the number of aneurysms detected and clinically followed,” said Jayme Strauss, chief clinical officer of Viz.ai. “The combination of detection with an ability to schedule patients for neurovascular specialist follow-up is an important advancement for aneurysm patients, helping patients obtain the necessary follow-up from this potentially deadly disease and driving improved outcomes on the population health level.”
The Viz ANEURYSM module is the latest addition to the company’s Viz Intelligent Care Coordination Platform, which is clinically validated and reimbursed by Medicare. Its clinical utility spans ischemic and hemorrhagic stroke, pulmonary embolism and aortic disease and is used in over 1,000 hospitals.